StockData
Milestone Pharmaceuticals Inc. logo

Milestone Pharmaceuticals Inc. (MIST) stock

MISTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 13, 2026Score 1/30
$0.52−0.14 (-20.63%)

Close on Nov 13, 2026Market cap $64.74MP/E –Yield –

Earnings

Milestone Pharmaceuticals's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Mar 19, 2027
Q4 FY2026 · estimated, before the open
Revenue, Q3 FY2026
$1.00M
EPS, Q3 FY2026
-$0.18
Latest guidance
None
No outlook given in releases

Quarterly results

Revenue and earnings per share from each of Milestone Pharmaceuticals's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource
Q4 FY2026ended Dec 31, 2026Mar 19, 2027Expected––––
Q3 FY2026ended Sep 30, 2026Nov 13, 2026before the open$1.00M–-$0.18Release
Q2 FY2026ended Jun 30, 2026Aug 12, 2026before the open$559.00K–-$0.21Release
Q1 FY2026ended Mar 31, 2026May 13, 2026before the open$200.00K–-$0.20Release
Q4 FY2025ended Dec 31, 2025Mar 20, 2026before the open$1.50M–-$0.16Release
Q3 FY2025ended Sep 30, 2025Nov 12, 2025before the open–––Release
Q2 FY2025ended Jun 30, 2025Aug 12, 2025before the open–––Release
Q1 FY2025ended Mar 31, 2025May 14, 2025before the open–––Release
Q4 FY2024ended Dec 31, 2024Mar 13, 2025before the open––-$0.19Release
Q3 FY2024ended Sep 30, 2024Nov 12, 2024before the open–––Release
Q2 FY2024ended Jun 30, 2024Aug 8, 2024during market hours––-$0.14Release
Q1 FY2024ended Mar 31, 2024May 13, 2024before the open––-$0.21Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Guidance

Milestone Pharmaceuticals has not given guidance in its releases

Many companies give their outlook only on the conference call or not at all. When Milestone Pharmaceuticals puts a forecast in an earnings release, it is listed here with the exact sentence.

Press releases

Releases Milestone Pharmaceuticals filed with the SEC as exhibits to Form 8-K or 6-K

  1. Pharmaceuticals Reports Third Quarter 2026 Financial Results and Announces Cost-Efficiency Measures Designed to Extend Cash Runway Through
    Results
  2. Milestone Pharmaceuticals Announces NMPA Approval
    News
  3. Quarter 2026 Financial Results and Provides Corporate Update
    Results
  4. Milestone Pharmaceuticals Announces First Quarter
    Results
  5. Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Update on the Commercial Launch of CARDAMYST™ (etripamil)
    Results
  6. Milestone Pharmaceuticals Announces U.S. Availability of CARDAMYST™
    News
  7. of Marketing Authorization Application for Etripamil Nasal Spray in PSVT by the European Medicines Agency
    News
  8. FDA Approval Investor Call December 15, 2025
    Update
  9. Milestone Receives FDA Approval of CARDAMYST™
    Update
  10. Reports Third Quarter 2025 Financial Results and Provides Regulatory and Corporate Update
    Results
  11. Reports Second Quarter 2025 Financial Results and Provides Regulatory and Corporate Update
    Results
  12. MONTREAL, Quebec and CHARLOTTE, N.C., July 11,
    News
  13. of $52.5 Million Public Offering of Common Shares, Pre-Funded Warrants, Series A Common Warrants and Series B Common Warrants
    News
  14. Milestone Pharmaceuticals Announces FDA Acceptance
    News
  15. Milestone Pharmaceuticals Submits Response to
    News

See a number that looks wrong?